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OBJECTIVES We sought to determine whether elevation of plasma creatine kinase muscle-brain fraction
(CK-MB) would be useful to triage patients with acute coronary syndromes (ACS) to early
angiography/revascularization.
BACKGROUND It is unknown whether the measurement of CK-MB is effective for triage to an aggressive
management strategy.
METHODS Patients in the Treat Angina With Aggrastat and Determine Cost of Therapy With an
Invasive or Conservative Strategy (TACTICS-TIMI) 18 study received aspirin, heparin, and
tirofiban for treatment of ACS, were randomized to an invasive or a conservative strategy
(angiography/revascularization between 4 and 48 h), and were followed up for a composite
end point of death, myocardial infarction, or rehospitalization for ACS.
RESULTS Of 2,220 patients, CK-MB was elevated in 826 (37%). Of the patients with negative
CK-MB, troponin T was elevated in 361 (31.2%). Event rates at 30 and 180 days were twice
as high in patients with elevated CK-MB than in patients without elevated CK-MB. Both
groups had similar benefit from an invasive strategy; there was no evidence of interaction
between CK-MB elevation and strategy on the composite end point at 30 or 180 days. When
patients were stratified according to both CK-MB and troponin status, there was evidence of
a benefit in the invasive strategy among patients who were CK-negative but troponin-positive
(odds ratios [95% confidence interval]: 0.13 [0.04 to 0.39] at 30 days and 0.29 [0.16 to 0.52]
at 180 days).
CONCLUSIONS Patients with minimal amounts of recent onset myonecrosis but elevated risk as indicated by
CK-MB and troponin, respectively, benefit most from invasive management. Determination
of troponin levels yielded significant information regarding triage to an invasive strategy,
particularly in CK-MB-negative patients. (J Am Coll Cardiol 2002;40:1044–50) © 2002
by the American College of Cardiology Foundation
Non-ST-segment elevation acute coronary syndromes
(ACS) account for more than 1,420,000 hospitalizations in
the U.S. (1). The pathophysiology in most cases centers
about plaque rupture, critical coronary arterial narrowing,
and intravascular thrombosis. A management strategy char-
acterized by treatment with either a low molecular weight
heparin or a platelet glycoprotein IIb/IIIa antagonist fol-
lowed by angiography and revascularization can reduce the
likelihood of subsequent recurrent angina, myocardial in-
farction (MI), and mortality (2,3). Given the large number
of patients who present with ACS, such an approach has
two major limitations. First, it requires performing coronary
angiography and percutaneous coronary intervention (PCI)
or coronary artery bypass surgery in high-risk as well as
low-risk patients who may not stand to benefit from this
approach. Second, it is resource-intensive and often requires
patient transfer to institutions with the facilities to perform
these procedures.
A variety of instruments have been proposed to stratify
patients with ACS according to risk and to the likelihood of
benefiting from an aggressive invasive strategy. Use of serum
biomarkers, indicating the presence of myocardial necrosis,
has been proposed as a useful strategy to triage patients to an
invasive or noninvasive management plan. In the Treat
Angina With Aggrastat and Determine Cost of Therapy
With an Invasive or Conservative Strategy (TACTICS-
TIMI) 18 study, a prospective substudy indicated a signif-
icant interaction between the presence of troponin T levels
0.01 ng/ml and an aggressive management strategy (3,4).
A recent consensus conference indicated that troponin was
the “preferred” marker for the diagnosis of MI (5). In
comparison with troponin determinations, measurement of
creatine kinase muscle-brain fraction (CK-MB) is more
universally available and, in many cases, less expensive to
perform. Levels of the isoforms of this enzyme, and perhaps
From the *Baylor College of Medicine and The Methodist-DeBakey Heart Center,
Houston, Texas; †Brigham and Women’s Hospital, Boston, Massachusetts; ‡Merck
Inc., West Point, Pennsylvania; and §Emory University, Atlanta, Georgia. Supported
by a grant from Merck, Inc.
Manuscript received December 18, 2001; revised manuscript received May 29,
2002, accepted June 19, 2002.
Journal of the American College of Cardiology Vol. 40, No. 6, 2002
© 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00
Published by Elsevier Science Inc. PII S0735-1097(02)02119-8
the total concentration of the enzyme, also become elevated
at an earlier stage than serum troponin (6). Consequently,
measurement of CK-MB may be useful at an early stage in
the evaluation of patients with ACS to decide whether rapid
triage to coronary angiography or a more conservative
approach is indicated. We prospectively assessed the
TACTICS-TIMI 18 study to test the hypothesis that
measurement of CK-MB could discriminate between pa-
tients who did or did not benefit from an early invasive
strategy.
METHODS
The methods and primary findings of TACTICS-TIMI 18
have been published (3). Patients presenting within the first
24 h of a chest pain syndrome believed to be ischemic and
who had either a history of coronary artery disease (CAD)
or an electrocardiographic ST-segment deviation, a T-wave
inversion, or an elevation of the CK-MB or troponin were
eligible. Patients were treated with aspirin 325 mg daily,
heparin given as a 5,000 U intravenous bolus followed by an
infusion at 1,000 U/h, and tirofiban given as a 0.4 g/kg/
min infusion for 30 min followed by 0.1 g/kg/min. They
were randomized to undergo either: 1) an early invasive
management strategy characterized by angiography 4 to
48 h after randomization, followed by anatomically directed
revascularization; or 2) a conservative strategy characterized
by exercise treadmill testing and angiography for test results
indicating either high risk or spontaneous recurrent isch-
emia. After PCI, tirofiban infusions were to be continued
for the following 24 h.
At the time of randomization, blood samples were drawn
every 8 h for the first 24 h and assayed locally. A sample
drawn at enrollment was assayed at a core laboratory for
creatine kinase (CK) and its MB fraction using the Bayer
ACS:180 CK-MB assay. The coefficient of variation for
CK-MB at this laboratory ranges between 5% and 7%.
Troponin T was also measured in this sample (Elecsys
10/10, Roche Diagnostics, Indianapolis, Indiana). Enroll-
ment MI was defined as an elevation in CK-MB above the
upper limit of normal on a sample obtained during the 24 h
before or after randomization, in the absence of a revascu-
larization procedure. The admission core laboratory speci-
men was used for the determination of enrollment MI, but
when a core laboratory value was not available, the site
determination was used.
The primary end point of the study was a composite of
death, MI, and rehospitalization for an ACS at six months.
The composite of death and MI was a secondary end point.
Myocardial infarction was determined as an increase in
CK-MB exceeding twice the normal value at the enrolling
site or the development of new Q-waves. Within 24 h after
a PCI, MI was defined as a threefold increase in CK-MB.
Statistical methods. Continuous variables are represented
as means and SDs; discrete variables are reported as median
values and 25th and 75th percentiles. Inferential compari-
sons were made using chi-square tests for continuous
discrete variables and appropriate parametric tests for con-
tinuous variables. Odds ratios (ORs) were calculated for
event rates at 30 days and six months. Logistic regression
was used to adjust ORs for baseline variables that were
different between patients with and without MI at the time
of enrollment. This adjustment is reported both before and
after the addition of troponin T 0.01 ng/ml to the model.
RESULTS
Of the 2,220 patients enrolled in TACTICS-TIMI 18, core
CK-MB values were available in 1,825 patients, and on-site
CK-MB values were used in 395. The CK-MB was elevated
in 826 (37%). This determination was based on core lab data
in 534 (65%) patients found to have enrollment MI. Core
lab troponin data were available in 1,825 patients. Of the
668 patients with elevated CK-MB who had troponin data
available, 625 (94%) had troponin T values 0.01 ng/ml,
while of the 1,157 patients without CK-MB elevation, 361
(31%) had troponin T values 0.01 ng/ml. The majority of
enrollment infarctions were characterized by peak CK
values 3 the upper limit of normal and by either
ST-segment depression or elevation (Table 1). Patients with
MI were more likely to be male or have a prior history of
smoking but were less likely to have other established risk
factors for CAD, to have been treated with an HMG Co-A
reductase inhibitor, or to have undergone a coronary artery
revascularization procedure (Table 1).
Among patients assigned to the invasive strategy, coro-
nary angiography was performed in 98% of CK-MB-
positive patients and 97% of CK-MB-negative patients
(Table 2). Among patients assigned to a conservative
strategy, 58% of patients with CK-MB elevation underwent
angiography compared with 47% of patients with normal
CK-MB (p  0.001). Multivessel CAD was also more
common in patients with CK-MB elevation. Regardless of
the assigned treatment strategy, revascularization was per-
formed more commonly in patients who were CK-MB-
positive, regardless of the extent of disease discovered at
Abbreviations and Acronyms
ACS  acute coronary syndromes
CAD  coronary artery disease
CK  creatine kinase
CK-MB  creatine kinase muscle-brain
fraction
GUSTO  Global Utilization of Strategies to
Open Occluded Coronary Arteries
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous coronary intervention
TACTICS-TIMI  Treat Angina With Aggrastat and
Determine Cost of Therapy With
an Invasive or Conservative
Strategy
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angiography (single-vessel disease 78% vs. 62%, p  0.001;
double-vessel disease 81% vs. 74%, p  0.08; triple-vessel
disease 76% vs. 72%, p  0.28). However, once a revascu-
larization procedure was undertaken, the procedure ap-
peared to be performed similarly regardless of CK-MB
status. Operator-reported success rates were also similar
between the two groups (Table 2).
At both the 30-day and six-month points, the composite
end point occurred more frequently in patients with
CK-MB elevation (Tables 3 and 4, Figs. 1 and 2). For the
primary composite, event rates were approximately 50%
higher in this group, while for the composite of death or
MI, they were approximately twice as high. Event rates also
increased as the peak value of CK increased (data not
shown).
Odds ratios for patients with, as well as for patients
without, CK-MB elevation favored the invasive strategy at
both 30 days and six months. After adjusting for differences
in baseline variables, the ORs were even more favorable for
both strategies, although, in patients without enrollment
MI, the 95% confidence limits exceeded unity for both the
double and triple composites at both time points (Table 4).
There was no evidence of statistical interaction between
CK-MB status and assigned treatment strategy: p  0.37
for the primary composite end point at 30 days and p 0.58
at six months; p  0.28 and 0.77 for the end point of death
or MI at 30 days and six months, respectively. After
adjustment for baseline characteristics, there was still no
evidence for a difference in treatment effect according to
elevation of the CK-MB (p  0.26, 0.38, 0.18, and 0.38,
respectively). When patients were stratified into tertiles of
CK elevation, the ORs favoring a benefit of the invasive
strategy on the primary composite end point at 30 days were
0.83 (95% confidence interval [CI], 0.25 to 2.78, p  0.76),
0.75 (95% CI, 0.20 to 2.76, p  0.66), and 1.05 (95% CI,
0.30 to 3.69, p  0.94) for the first through third tertiles,
respectively. At 180 days the respective ORs were 0.92 (95%
CI, 0.35 to 2.41, p 0.86), 0.95 (95% CI, 0.34 to 2.66, p
0.92), and 0.45 (0.17 to 1.21, p  0.12).
Stratification of patients according to both CK-MB and
troponin at the time of study enrollment (Table 5) indicated
that determination of both values yielded important infor-
Table 1. Demographic Characteristics
CK-MB  CK-MB  p Value
Weight (kg) 84.7  17.9 83.3  18.5 0.0768
Age (yrs) 62.1  11.9 61.6  11.5 0.2680
Male 73%, n  606 62%, n  857 0.001
Diabetes 26%, n  213 29%, n  400 0.139
Smoker
Current 35%, n  286 29%, n  392 0.002
Former (ever) 74%, n  608 70%, n  967 0.040
Hypertension 60%, n  492 70%, n  975 0.001
Hyperlipidemic 55%, n  453 64%, n  893 0.001
On a statin 19%, n  154 28%, n  390 0.001
Prior MI 33%, n  271 43%, n  595 0.001
Prior CABG 16%, n  135 25%, n  349 0.001
Prior PCI 18%, n  150 33%, n  462 0.001
On heparin before
randomization
2%, n  19 2%, n  31 0.907
On aspirin before
randomization
60%, n  493 71%, n  984 0.001
ST elevation 16%, n  128 9%, n  126 0.001
ST depression 36%, n  299 27%, n  378 0.001
T-wave inversion only 16%, n  133 24%, n  329 0.001
No ECG  37%, n  309 43%, n  597 0.012
Troponin T  0.01 ng/ml 94%, n  625 32%, n  361 0.001
CABG  coronary artery bypass grafting; CK-MB  muscle-brain fraction of
creatine kinase; ECG  electrocardiogram; MI  myocardial infarction; PCI 
percutaneous coronary intervention.
Table 2. Procedural Details
Invasive Conservative
CK-MB  CK-MB  p Value CK-MB  CK-MB  p Value
Duration of tirofiban (h) 48.4 48.1 0.0012 52.1 49.1 0.068
(median 25th/75th %) (47.3, 62.5) (38.3, 55.4) (48, 68.5) (48, 69.6)
Angiogram performed 98% 97% 0.471 58% 47%  0.001
# of vessels diseased  0.001 0.007
0 7.4% 17% 4.7% 12%
1 26% 25% 26% 28%
2 31% 26% 31% 23%
3 36% 32% 38% 36%
LMCA 8.3% 8.6% 0.893 11% 9.9% 0.54
Any revascularization 71% 54%  0.001 44% 32%  0.001
PCI performed 51% 35%  0.001 32% 21%  0.001
Stent placed 84% 80%, 198/247 0.334 88% 85% 0.49
Number of vessels attempted 1.1  0.58 1  0.49 0.1314 1.1  0.52 1.1  0.53 0.20
Duration of tirofiban after PCI in
days (median 25th/75th %)
0.97 (0.55, 1.3) 1.03 (0.57, 1.35) 0.1294 0 (0, 0.56) 0.01 (0, 0.65) 0.24
PCI success 92% 96% 0.045 95% 95% 0.81
2nd PCI performed 4.7% 4.1% 0.743 4.6% 6.2% 0.56
CABG performed 21% 19% 0.507 15% 12% 0.11
# of grafts placed 31  0.9, n  87 2.9  0.99 0.1933 31  0.95 3.0  0.99 0.55
CABG  coronary artery bypass grafting; CK-MB  muscle-brain fraction of creatine kinase; LMCA  left main coronary artery; PCI  percutaneous coronary intervention.
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mation. When both markers were negative, there was
almost no benefit to an invasive strategy; when both were
positive, the benefit appeared to be modest. By far, the
greatest benefit was observed in patients with negative
CK-MB but positive troponin T (ORs, 0.13 to 0.33).
Univariate logistic regression analysis confirmed highly
significant interactions between CK-MB-negative but
troponin-positive status and the composite end point. At 30
days the OR for the benefit of invasive versus conservative
management was 0.13 (95% CI, 0.05 to 0.40, p  0.001),
and at 180 days it was 0.24 (95% CI, 0.12 to 0.50, p 
0.001).
DISCUSSION
Both clinical and economic considerations favor the devel-
opment of improved triage strategies to select patients who
are most likely to benefit from invasive management strat-
egies. Measurement of CK-MB is an established technique
for diagnosing MI, and CK-MB might be considered a
likely candidate biomarker for development of a triage
strategy. Although most index infarctions within
TACTICS-TIMI 18 were relatively small, we nonetheless
observed that rates of recurrent ischemic events during the
first six months after presentation were 50% to 100% higher
among patients with elevations of CK-MB. Despite a nearly
Table 3. Cardiac Events at 30 and 180 Days
A. Individual Event Rates at 30 Days
CK-MB  (n  826) CK-MB  (n  1,394)
Inv. Cons. p Value Inv. p Value p Value
Death 13 (3.1%) 11 (2.7%) 0.7 12 (1.7%) 7 (1.0%) 0.24
Myocardial infarction 16 (3.8%) 36 (8.8%) 0.003 18 (2.6%) 28 (4.0%) 0.13
Rehospitalization for angina 19 (4.6%) 33 (8.1%) 0.038 19 (2.7%) 28 (4.0%) 0.18
B. Individual Event Rates at 180 Days
CK-MB  (n  826) CK-MB  (n  1,394)
Inv. Cons. p Value Inv. p Value p Value
Death 19 (4.6%) 21 (4.1%) 0.7 18 (2.6%) 18 (2.6%) 1.0
Myocardial infarction 28 (6.7%) 41 (8.8%) 0.09 25 (3.6%) 35 (5.0%) 0.19
Rehospitalization for angina 49 (11.8%) 63 (15.4%) 0.13 74 (10.6%) 89 (12.8%) 0.18
CK-MB  muscle-brain fraction of creatine kinase; Cons.  conservative; Inv.  invasive.
Table 4. Odds Ratios for Invasive and Conservative Management According to the Presence of Enrollment MI
A. Unadjusted OR
CK-MB  CK-MB 
OR for Inv. vs. Cons. Rx 95% CI p Value OR for Inv. vs. Cons. Rx 95% CI p Value
30-day death/MI 0.82 0.48, 1.39 0.43 0.52 0.31, 0.87 0.015
30-day composite 0.85 0.55, 1.29 0.24 0.54 0.35, 0.82 0.012
6-month death/MI 0.76 0.49, 1.17 0.27 0.72 0.47, 1.11 0.109
6-month composite 0.90 0.67, 1.21 0.21 0.76 0.47, 0.93 0.053
B. OR Adjusted for Baseline Characteristics
CK-MB  CK-MB 
OR for Inv. vs. Cons. Rx 95% CI p Value OR for Inv. vs. Cons. Rx 95% CI p Value
30-day death/MI 0.78 0.45, 1.33 0.353 0.50 0.29, 0.85 0.010
30-day composite 0.77 0.50, 1.18 0.231 0.55 0.35, 0.85 0.007
6-month death/MI 0.78 0.50, 1.22 0.270 0.65 0.42, 1.02 0.060
6-month composite 0.82 0.61, 1.11 0.203 0.68 0.48, 0.96 0.029
C. OR Adjusted for Baseline Characteristics Including Troponin Elevations
CK-MB  CK-MB 
OR for Inv. vs. Cons. Rx 95% CI p Value OR for Inv. vs. Cons. Rx 95% CI p Value
30-day death/MI 0.63 0.34, 1.18 0.147 0.45 0.25, 0.83 0.010
30-day composite 0.64 0.40, 1.03 0.065 0.49 0.30, 0.80 0.004
6-month death/MI 0.70 0.42, 1.17 0.173 0.70 0.42, 1.17 0.173
6-month composite 0.79 0.57, 1.10 0.158 0.63 0.42, 0.94 0.022
CI  confidence interval; CK-MB  muscle-brain fraction of creatine kinase; Cons.  conservative; Inv.  invasive; MI  myocardial infarction; OR  odds ratio.
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Figure 1. Kaplan-Meier estimates of survival free of the composite end point according to creatine kinase muscle-brain fraction (CK-MB) status and
assignment to an invasive or conservative strategy.
Figure 2. Kaplan-Meier estimates of survival free of death or myocardial infarction according to creatine kinase muscle-brain fraction (CK-MB) status and
assignment to an invasive or conservative strategy.
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50% reduction in the composite ischemic primary end point
at 30 days among CK-MB-positive patients assigned to the
invasive strategy, we did not observe statistical evidence that
at six months the benefit of the invasive strategy was greater
for these patients. Patients with, as well as without, elevated
levels of CK-MB appeared to benefit from assignment to an
invasive management strategy. Odds ratios were less than
unity for both groups, although there was a weak trend
toward an interaction at 30 days. Although event rates
seemed to increase with increases in the peak CK value, we
did not observe a parallel increase in the benefit of the
invasive strategy. In contrast, our previously published
findings using the troponin T assay indicated significant
differences in benefit at 30 days and six months and
progressive increases in this benefit with decreasing levels of
troponin. Interaction terms for positive versus negative
troponin at the 30-day and six month points were 0.013 and
0.003, respectively (3).
Several features of the current study may help explain
these observations. First, although the group with positive
biomarkers is event-rich and is highly likely to have signif-
icant CAD, a recent period of prolonged occlusion of a
coronary artery is required to cause myonecrosis. We chose
to examine CK-MB in this study because histological
studies have linked it unequivocally to myocardial necrosis
(7,8) and because it is released rapidly after cell death. The
ability of plasma CK-MB, and particularly its isoforms, to
rise quickly after the onset of cell death is useful in
diagnosing MI and reinfarction. In a recent multicenter
study of patients with MI, values of CK-MB mass were
elevated in 16% and 39% of patients at 2 and 4 h,
respectively, after the onset of chest pain, compared with
10% and 37% for troponin T (6), whereas in another
single-center study, the sensitivity at 3 h for CK-MB mass
5 g/l was 47%, while that for troponin T 0.06 mg/l
was 20% (9).
Relationship between CK-MB and troponin. Although,
by definition, patients in the current study without CK-MB
elevation did not have traditional evidence of recent myo-
necrosis, 31% had elevation of troponin T. An interesting
observation was that this group appeared to have an ampli-
fied benefit from the invasive strategy. Although the exact
magnitude of this finding cannot be firmly established in a
relatively small number of patients (383), it does provide
evidence of the heterogeneity of patients without CK-MB
elevation. While the ORs for patients who had elevation of
neither enzyme were close to unity, those who had evidence
of troponin elevation despite negative CK-MB had ORs
0.33. Early investigations suggested that, because of its
relatively small size and presence in the myocardial cytosol,
troponin T might be an indicator of myocardial ischemia
rather than cell death (10). However, the relationship
between troponin release and the presence of necrosis has
not yet been established. It is possible that patients in this
latter group had transient reversible ischemia or that they
had more temporally remote myocardial necrosis with sub-
sequent recovery and a greater quantity of viable myocar-
dium, which was protected by a revascularization strategy.
This analysis represents a relatively small subgroup within
the study and, as such, should be regarded as hypothesis-
generating. If confirmed in subsequent studies, these data
suggest that a dual marker triage strategy might ultimately
be useful for patient triage and that abandonment of
Table 5. Logistic Regression (Univariate) for Death/MI and Composite End Point Stratified





OR for Inv. vs.
Cons. Rx 95% CI p Value
CK-/troponin  (n  662)
30-day death/MI (n  20) 3.0% 3.1% 0.97 0.40, 2.36 0.945
30-day composite (n  41) 6.0% 6.4% 0.92 0.49, 1.73 0.794
180-day death/MI (n  32) 4.5% 5.2% 0.85 0.42, 1.73 0.653
180-day composite (n  107) 17.3% 15.0% 1.18 0.78, 1.79 0.436
CK-/troponin  (n  383)
30-day death/MI (n  28) 2.0% 13.3% 0.13 0.04, 0.39  0.001
30-day composite (n  42) 3.0% 19.9% 0.12 0.05, 0.30  0.001
180-day death/MI (n  35) 5.0% 13.8% 0.325 0.15, 0.70 0.004
180-day composite (n  61) 8.4% 24.3% 0.29 0.16, 0.52  0.001
CK/troponin  (n  123)
30-day death/MI (n  3) 0% 4.3% — — —
30-day composite (n  6) 5.7% 4.3% 1.34 0.26, 6.92 0.727
180-day death/MI (n  5) 1.9% 5.7% 0.32 0.03, 2.93 0.311
180-day composite (n  19) 13.2% 17.1% 0.74 0.27, 2.02 0.551
CK/troponin  (n  559)
30-day death/MI (n  45) 7.0% 9.2% 0.75 0.40, 1.38 0.348
30-day composite (n  70) 10.8% 14.3% 0.73 0.44, 1.21 0.220
180-day death/MI (n  63) 11.2% 11.4% 0.98 0.58, 1.66 0.950
180-day composite (n  119) 19.2% 23.4% 0.78 0.52, 1.17 0.225
CI confidence interval; CK creatine kinase; Cons. conservative; Inv. invasive; MImyocardial infarction; OR odds
ratio.
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CK-MB determination in favor of troponin alone may be
premature.
Implications for early triage. The TACTICS-TIMI 18
study did not examine the effects of an immediate revascu-
larization strategy on clinical outcomes. Rather, the invasive
strategy relied on “upstream” anti-platelet therapy and was,
by intent, designed to test invasive management after a
minimum of 4 h of pharmacologic quiescence of an ACS. In
patients with ACS, the majority of recurrent events consist
of reinfarction and recurrent ischemia rather than the
sequelae of ventricular dysfunction, as is seen in patients
with ST-segment-elevation infarction (11,12). An analysis
of patients enrolled in the Global Utilization of Strategies to
Open Occluded Coronary Arteries (GUSTO) IIb study
indicated that the “front-loading” of events within the first
24 h previously observed in patients with ST-segment-
elevation infarction is not present in patients with non-ST-
segment ACS (13). For the purpose of assessing a strategy
designed to manage longer-term sequelae of ACS, a bi-
omarker that has a longer plasma half-life would be ex-
pected to be a better discriminator of patients who have
high-risk coronary arterial lesions. Biomarkers that are
released and cleared rapidly, such as CK-MB or its iso-
forms, may prove to be more useful discriminators in studies
evaluating mechanical reperfusion strategies in the first few
hours after presentation of patients with non-ST-segment
elevation ACS.
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